PDX Models

PRECEDO is dedicated to providing accurate, reliable, and consistent PDX models-based services to support global drug development.

PDX Models

Leveraging China’s first nationally approved renewable primary cell biobank (Human Genetic Resource Preservation License, Approval No.: [2022] BC0101), PRECEDO has established a large-scale PDX model repository covering more than 30 cancer types—including lung, colorectal, gastric, breast, liver, pancreatic, and ovarian cancers—with over 500+ pathologically validated PDX models.

1

WHY Choose PRECEDO PDX?

  • Comprehensive Model Annotation: Each model is accompanied by complete clinical data (diagnosis, stage, treatment history), pathological data (H&E, IHC), and molecular data (WES, RNA-seq), enabling multi-dimensional analysis.
  • Broad Applications: Supports a variety of in vivo efficacy study formats, including subcutaneous, orthotopic, and metastatic models, for diverse drug modalities—small molecules, antibodies, ADCs, PROTACs, and more.
  • Integrated Services: Offers customizable support including PK/PD studies, biomarker analysis, and combination therapy screening, covering the entire drug development continuum from early discovery to IND-enabling studies.

A Lung Cancer PDX Case :

1

1

1 1

 

 

Biobank

Tailored to Your Needs —

Precision Models for Your Research

Not finding what you need? Submit a custom sample request to access models tailored to your specific research requirements.

Reprogramming Cells, Empowering Medicine

GO

Sample Request

Registration of Human Sample Requirements

Action
Remove
Submit

Sample Request

Registration of Human Sample Requirements

Action
Remove
Submit